Hier finden Sie die aktuellen Lungenstudien:
Studiennummer: AstraZeneca: D4191C00119
Studientitel: A Multi-Site, International Observational Study to Understand the Impact Of the COVID-19 Pandemic on the Treatment of Patients with Stage III Unresectable Non-Small Cell Lung Cancer (NSCLC)
Status: offen
Verantwortlicher Arzt: Hr. Ferentinos
Studiennummer: ANTELOPE (AIO-TRK-0122)
Studientitel: Atezolizumab/Carboplatin/nab-Paclitaxel vs. Pembrolizumab/Platinum/Pemetrexed in metastatic TTF-1 negative lung adenocarcinoma
Status: offen
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: CA224-104
Studientitel: A Phase 2 Randomized Double-blind Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy as First Line Treatment for Participants with Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Status: Rekrutierungsstopp
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: COCOON
Studientitel: A Phase 2, open-label, randomized trial evaluating the impact of enhanced versus standard dermatologic management on selected dermatologic adverse events among patients with locally advanced or metastatic EGFR-mutated NSCLC treated first-line with amivantamab + lazertinib
Status: offen
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: DOLPHIN
Studientitel: A Phase II randomized Study to evaluate the efficacy and safety of Cisplatin or Carboplatin /Etoposide and concomitant Radiotherapy combined with Durvalumab followed by Maintenance Therapy with Durvalumab versus Cisplatin or Carboplatin / Etoposide and concomitant Radiotherapy in Patients with limited disease Small Cell Lung Cancer.
Status offen
Verantwortlicher Arzt Dr. Ertl
Studiennummer: IMforte (GO43104)
Studientitel: A Phase III, randomized, open-label, multicenter study of lurbinectedin in combination witz atezolizumab compared with atezolizumab as maintenance therapy in participants with extensive-stage small-cell lung cancer (ES-SCLC) following first-line inducion therapy with carboplatin, etoposide and atezoliumab
Status: Rekrutierungsstopp
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: A2A-005
Studientitel: A randomized, double-blind, placebo-controlled, Phase 2 study evaluating efficacy and safety of inupadenant in combination with carboplatin and pemetrexed in adults with nonsquamous non-small cell lung cancer who have progressed on immunotherapy
Status: offen
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: MK7339-006
Studientitel: A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer
Status: Rekrutierungsstopp
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: MK7339-008
Studientitel: A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Status: Rekrutierungsstopp
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: NICITA (AIO-TRK/YMO-0419)
Studientitel: Nivolumab with chemotherapy in pleural mesothelioma after surgery
Status: Rekrutierungsstopp
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: OCTOPUS
Studientitel: An ambisspective observational study describing diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice, to assess treatment effectiveness and quality of life.
Status: offen
Verantwortlicher Arzt: Hr. Ferentinos
Studiennummer: PACIFTC-R (Astra Zeneca D4194R00005)
Studientitel: First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
Status: Rekrutierungsstopp
Verantwortlicher Arzt: Dr. Ertl
Studiennummer: TigerMeso (NCT05538806)
Studientitel: TTFields in general routine clinical care in patients with pleural mesothelioma study
Status: offen
Verantwortlicher Arzt: Hr. Ferentinos
